Neocytogen Therapeutics is a biotechnology company focusing on universal cell and gene therapy, committed to developing innovative therapies for malignant tumors and chronic diseases. The company's core technologies include universal CAR-X platform, iPSC platform, next generation oncolytic virus platform, and exosome technology platform. The founding team of Neocytogen is composed of senior scientists from the National University of Singapore and Nanyang Technological University. The company is headquartered in Singapore, with R&D centers in Singapore and Shanghai, China. We are also building an integrated center of R&D and production in Singapore to support future technology translation and clinical applications, enabling us to become a global leader in universal cell therapy.
For more information, please refer to our website.
Company Details
- Founded
- -
- Address
- 1 Venture Avenue, Singapore, #01-08,perennial Business City,singapore
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.neocytogen.com/en
- HQ
- Singapore, Singapore
Neocytogen Theraputics Questions
Neocytogen Theraputics's website is http://www.neocytogen.com/en
Neocytogen Theraputics's LinkedIn profile is https://sg.linkedin.com/company/neocytogen-therapeutics-pte-ltd
Neocytogen Theraputics's industry is
Biotechnology Research
Neocytogen Theraputics's top competitors are
Oregenx,
Myscada Asia,
Sunbird Bio,
Carmine Therapeutics,
Czech Society For Extracellular Vesicles (Czesev),
Blue Unicorn Capital,
Sandsam Corporation,
Imcb Division Of Cell And Molecular Therapy (Cmt),
Medbank,
Co11ab Novena.
Neocytogen Theraputics's categories are Biotechnology Research
Neocytogen Theraputics's founding year is 2024
